Do you want to read an article? Please log in or register.
Safety and outcomes of advanced IBD therapies in patients with HIV: a propensity-matched cohort analysis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Impact of Type 2 Diabetes on Clinical Outcomes and Advanced Therapy Use in Patients with Crohn's Disease: a Real-World Propensity Score-Matched Analysis
J Crohns Colitis
Massironi S, Solitano V, Furfaro F, D'Amico F, Zilli A, Allocca M, Peyrin-Biroulet L, Jairath V, Danese S
doi: 10.1093/ecco-jcc/jjaf157
Inflammatory Bowel Disease
Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource
Inflamm Bowel Dis
Yan K, Vuyyuru SK, Taylor A, Figueredo G, Raine T, Sanon M, Naessens D, Munje C, Moran GW
doi: 10.1093/ibd/izaf276
Inflammatory Bowel Disease
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis
Adv Ther
Schreiber S, Danese S, Colombel JF, Hisamatsu T, Irving PM, Park H, Kim DH, Lee YN, Hanauer SB
doi: 10.1007/s12325-025-03447-6
Inflammatory Bowel Disease
Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis
Inflamm Bowel Dis
Nishida Y, Hosomi S, Fujimoto K, Kobayashi Y, Nakata R, Maruyama H, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Fujiwara Y
doi: 10.1093/ibd/izaf302
RECOMMENDED
Inflammatory Bowel Disease
Efficacy of 5-Aminosalicylic Acid Continuation versus Discontinuation in Patients with Ulcerative Colitis Escalated to Advanced Therapy: A Systematic Review and Meta-Analysis of Adjusted Effect Estimates
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Sul HH, Gewehr DM, Kang H, Junior OR, Ungaro RC, Bernstein CN
doi: 10.1093/ecco-jcc/jjaf202
Inflammatory Bowel Disease
Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD services
J Crohns Colitis
Hawthorne AB, Christiansen P, Arnott I, Cummings F, Dobson L, Kent A, Limdi JK, Mulligan RJ, Parkes GC, Rees F, Selinger CP, Turner J, Woo N, Younge L, Contributors to the IBD UK Task & Finish group, IBD Service Survey Collaborators, Lamb CA
doi: 10.1093/ecco-jcc/jjag005
Inflammatory Bowel Disease
Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis
Inflamm Bowel Dis
Desai A, Habib H, Khataniar H, Farraye FA, Sehgal P, Barnes EL, Kochhar GS, Hashash JG
doi: 10.1093/ibd/izaf301
Inflammatory Bowel Disease
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
Lancet Gastroenterol Hepatol
Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ, COSTA Study Group
doi: 10.1016/S2468-1253(25)00291-2
Inflammatory Bowel Disease
Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis
J Crohns Colitis
Bayoumy AB, Clarke LM, Deepak P, Desai A, Sehgal P, Gorelik Y, Bar-Yoseph H, Villumsen M, Mulder CJJ, Stenvers DJ, Tushuizen ME, de Boer NKH
doi: 10.1093/ecco-jcc/jjaf181